MANTLE CELL LYMPHOMA (MCL)

This is the first study in people testing a new drug called LTZ-301 for adults with non-Hodgkin lymphoma that has come back or stopped responding to at least two prior treatments. The main goals are to find a safe dose and see how the body handles the drug, while also checking fo…

This study is testing a combination of two drugs, pirtobrutinib and rituximab, for adults newly diagnosed with a slow-growing form of mantle cell lymphoma, a type of blood cancer. The goal is to see if this drug pair can effectively control the disease while causing fewer side ef…

This study is testing a two-part treatment for B-cell lymphoma that has come back or not responded to other therapies. First, doctors modify a patient's own immune cells (CAR-T cells) to attack the cancer. Then, they add an immunotherapy drug (sintilimab) for up to a year to help…

This early-stage trial is testing the safety and best dose of a new type of CAR-T cell therapy. The therapy uses a patient's own modified immune cells to target two proteins (CD19 and CD22) on lymphoma cells. It is for adolescents and adults whose B-cell non-Hodgkin lymphoma has …

This study is testing a new type of personalized cell therapy for adults whose B-cell blood cancers have come back or not responded to standard treatments. The therapy, called CAR-T, is engineered to attack cancer cells using two targets (CD19 and CD20) instead of one, which may …

This study is testing a new combination of three targeted drugs (orelabrutinib, lisaftoclax, and rituximab) for people newly diagnosed with a high-risk form of mantle cell lymphoma, an aggressive blood cancer. The goal is to see if this combination can effectively control the dis…

This study is testing a combination of three drugs (pomalidomide, orelabrutinib, and zuberitamab) in people newly diagnosed with mantle cell lymphoma, a type of blood cancer. The main goal is to see how well this combination clears the body of tiny amounts of leftover cancer cell…

This study is testing a combination of two drugs, orelabrutinib and rituximab, for people newly diagnosed with a type of blood cancer called mantle cell lymphoma (MCL). The main goal is to see how well this treatment can put the cancer into complete remission. Researchers will al…

This is a first-in-human study testing a new oral drug called NX-5948 in adults with advanced B-cell blood cancers that have returned or stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. The study will enroll …

This study is creating a national registry to track how nearly 3000 people in Germany with various blood cancers are treated in real-world settings. It will document what treatments patients receive, how they respond, and how their quality of life is affected over time. The goal …